Posted by Michael Wonder on 30 Aug 2018
Proposal to list sapropterin for use in pregnancy by women with phenylketonuria
30 August 2018 - PHARMAC is seeking feedback on a proposal to fund sapropterin tablets, a treatment for the rare condition phenylketonuria, for women who are pregnant or actively planning a pregnancy and require pharmacological support to manage phenylketonuria in pregnancy.
Sapropterin (Kuvan) would be funded from 1 November 2018, through a provisional agreement with BioMarin Pharmaceutical Australia.
From 1 November 2018, women with phenylketonuria who are pregnant or actively planning a pregnancy and require pharmacological support to manage their phenylketonuria in pregnancy would be eligible for funded treatment with sapropterin, subject to Special Authority criteria.
